Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Other Financing Activities
Financing cash flows not reported separately.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities turns negative
Q2 FY2026 other financing activities was -$15.78M, compared with $763K a year earlier. Trailing-twelve-month other financing activities was $34.66M.
Context
- Other financing activities amounted to 69.9% of revenue in FY2025, down 6858.6 pp from a year earlier.
- Other financing activities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near -$15.78M or moves back toward the trailing-twelve-month quarterly average of $8.67M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 49.54M USD
- Year-over-year change
- +336.8%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.54M | +336.8% |
| FY2024 | 2024-12-31 | (20.92M) | -322.4% |
| FY2023 | 2023-12-31 | 9.41M | +150.5% |
| FY2022 | 2022-12-31 | (18.63M) | -214.3% |
| FY2021 | 2021-12-31 | (5.93M) | — |
Other Financing Activities vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's LTM Jun 2026 other financing activities of $34.66M is the 2nd largest of the 4 companies compared; the peer median is $0.
- Its year-over-year change of +90.6% is the 2nd highest of 4, against a peer median of -100.0%.
- Other financing activities amounts to 48.7% of revenue for VRDN, versus a peer median of 47.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.53T | +92313235.1% | — | 4662722470.8% | |
| LTM Jun 2026 | $34.66M | +90.6% | — | 48.7% | |
| LTM Mar 2026 | $3.59M | -136.4% | -24.2% | 47.2% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding VRDN) | $0 | -100.0% | -24.2% | 47.2% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.47M | 19.77M | 67.17M | 42.15M | 44.3M |
| Change in Working Capital | 1.72M | 15.96M | (9.43M) | 9.6M | 23.03M |
| Accounts Receivables | (451K) | 349K | 0 | 102K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.66M | 11.52M | (12.04M) | (73K) | 6.56M |
| Other Working Capital | 520K | 4.09M | 2.62M | 9.57M | 16.47M |
| Other Non-Cash Items | 8.52M | 54K | (4.71M) | (14.66M) | (1.58M) |
| Operating Cash Flow | (54.58M) | (93.84M) | (184.17M) | (232.32M) | (276.39M) |
| Capital Expenditures | (338K) | (797K) | (898K) | (511K) | (495K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.43M) | (223.26M) | (407.88M) | (695.07M) | (579.28M) |
| Sales of Investments | 114.4M | 108.94M | 314.53M | 466.93M | 542.21M |
| Other Investing Activities | 79K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (74.29M) | (115.13M) | (94.25M) | (228.65M) | (37.56M) |
| Debt Repayment | 0 | 5M | 15M | 0 | 28.88M |
| Common Stock Issued | 114.24M | 291.87M | 125.07M | 453.66M | 348.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.93M) | (18.63M) | 9.41M | (20.92M) | 49.54M |
| Financing Cash Flow | 125.28M | 322.24M | 225.67M | 457.74M | 426.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.6M) | 113.28M | (52.75M) | (3.23M) | 112.79M |
| Free Cash Flow | (54.92M) | (94.64M) | (185.07M) | (232.83M) | (276.89M) |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.